Immediate Impact
1 from Science/Nature 66 standout
Citing Papers
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
2023 Standout
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
2023 Standout
Works of Mark Jenkins being referenced
Systematic review of clinical practice guidelines to identify recommendations for sleep in type 2 diabetes mellitus management
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Mark Jenkins | 14 | 95 | 40 | 43 | 14 | 223 | |
| Joseph Meyerson | 7 | 61 | 17 | 45 | 21 | 278 | |
| Jacob Harbo Andersen | 13 | 56 | 19 | 39 | 16 | 247 | |
| Alex M. Blaicher | 37 | 90 | 54 | 20 | 10 | 291 | |
| Shivali Aggarwal | 21 | 35 | 46 | 85 | 16 | 270 | |
| Robert Joseph | 23 | 49 | 10 | 23 | 22 | 287 | |
| Clare Fowler | 8 | 33 | 20 | 27 | 14 | 270 | |
| Kathryn Witzeman | 6 | 63 | 6 | 41 | 16 | 283 | |
| Sanjay Kukreja | 11 | 59 | 12 | 29 | 18 | 232 | |
| Alba Calderone | 11 | 103 | 14 | 106 | 12 | 248 | |
| Jonathan D. Hafferty | 17 | 13 | 16 | 40 | 13 | 197 |
All Works
Login with ORCID to disown or claim papers
Loading papers...